PaySign Inc Class B ( (PAYS) ) has released its Q2 earnings. Here is a breakdown of the information PaySign Inc Class B presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paysign, Inc. is a financial services company specializing in prepaid card programs, pharma patient affordability solutions, and integrated payment processing, primarily serving the healthcare industry. In its second quarter of 2025, Paysign reported a significant increase in total revenues, reaching $19.08 million, a 33.1% rise from the previous year. The company also saw a substantial growth in net income, which nearly doubled to $1.39 million, and adjusted EBITDA more than doubled to $4.51 million. Key performance highlights include the addition of 123 net plasma centers and seven new pharma patient affordability programs, contributing to a 189.9% increase in pharma revenue. Despite a decrease in plasma revenue due to industry-wide oversupply, the company’s overall gross profit increased by 55%, driven by the strong performance in the pharma sector. Looking forward, Paysign plans to expand its plasma offerings and scale its operations to meet the growing demand for its pharma solutions, with expectations of continued revenue growth and strategic expansion in the healthcare market.